Timothy Samec
Overview
Explore the profile of Timothy Samec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Revilla Lopez J, Enciso Chancahuana R, Meza Cruzado S, Melendez Rios F, Negron Abril Y, Sumarriva D, et al.
Case Rep Oncol
. 2025 Feb;
18(1):247-254.
PMID: 39991021
Introduction: Renal angiomyolipomas (AMLs) are rare tumors categorized within the perivascular epithelioid cell tumor (PEComa) family, most of which are benign, except for epithelioid AMLs (EAML) with malignant potential. EAML...
2.
Rushton T, Krause H, Samec T, Elliott A, Karnezis A, Toboni M, et al.
Gynecol Oncol
. 2024 Oct;
191:80-85.
PMID: 39366033
Objective: Targeted therapy in folate receptor alpha (FOLR1)-positive high grade serous ovarian carcinoma (HGSOC) is now a mainstay for platinum-resistant disease. However, the rate of FOLR1-positivity in low grade serous...
3.
Malla M, Deshmukh S, Wu S, Samec T, Olevian D, El Naili R, et al.
Cancer Gene Ther
. 2024 Aug;
31(10):1547-1558.
PMID: 39174744
The expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival....
4.
Rustgi N, Wu S, Samec T, Walker P, Xiu J, Lou E, et al.
Cancer Res Commun
. 2024 May;
4(6):1399-1409.
PMID: 38717153
Significance: Advanced gastric cancer has a relatively dismal outcome with a 5-year overall survival of less than 10%. Furthermore, while comprehensive molecular analyses have established molecular subtypes within gastric cancers,...
5.
Kareff S, Trabolsi A, Krause H, Samec T, Elliott A, Rodriguez E, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672653
Tipifarnib is the only targeted therapy breakthrough for -mutant (mt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of mt cancers are difficult to explore...
6.
Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, et al.
Res Sq
. 2024 Jan;
PMID: 38234761
The expression of the protein is highly variable in several malignancies including colorectal cancer (CRC) and high levels are associated with aggressive clinicopathological features and worse patient survival. CRC is...
7.
Darabi S, Xiu J, Samec T, Kesari S, Carrillo J, Aulakh S, et al.
Med Oncol
. 2023 Jun;
40(7):197.
PMID: 37291277
Gliomas are the most prevalent neurological cancer in the USA and care modalities are not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep...
8.
Samec T, Alatise K, Boulos J, Gilmore S, Hazelton A, Coffin C, et al.
Mol Ther Nucleic Acids
. 2022 Oct;
30:95-111.
PMID: 36213692
Ovarian cancer has shown little improvement in survival among advanced-stage patients over the past decade. Current treatment strategies have been largely unsuccessful in treating advanced disease, with many patients experiencing...
9.
Samec T, Boulos J, Gilmore S, Hazelton A, Alexander-Bryant A
Mater Today Bio
. 2022 Apr;
14:100248.
PMID: 35434595
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery...